Skip to Content

Clinical Trial Details

Cabozantinib Versus Sunitinib for Renal Cancer That Has Spread Outside the Kidney

A Randomized II Study Comparing Cabozantinib with COmmercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma.

Objective

To determine if patients with renal cancer treated with Cabozantinib will have longer period of time with tumor growth compared to patients treated with Sunitinib.

Inclusion Criteria:
Must have measureable disease.

Exclusion Criteria:
No prior chemotherapy for renal cell cancer.

IRB Protocol Number
A031203

Clinical Trial Categories

  • Genitourinary Cancer
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000